Baxalta

Baxalta was a corporation based in Bannockburn, Illinois. Established in 2015, the firm was a developer of bio-pharmaceutical products. The firm offered bio-pharmaceuticals for the treatment of hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, and other chronic. Its therapies were available in more than 100 countries and it has biological manufacturing operations across 12 facilities, including recombinant production and plasma fractionation. The assets of the firm were managed by the executive management team. The firm merged with Shire creating the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions.